Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation

Frontiers in Immunology

卷:13

Alexandra Beurton¹  Neila Benameur²  Cary Gunn³  Rick Hockett³  Sophia de Alba³  Sasi Mudumba³  Julien Mayaux⁵  Alexandre Demoule⁵  Thibaut Chazal⁶  Jehane Fadlallah⁶  Zahir Amoura⁶  Julien Haroche⁶  Alexis Mathian⁶  Charles-Edouard Luyt⁷  Alain Combes⁷  Hans Yssel⁸  Makoto Miyara⁸  Laetitia Claër⁸  Mo Atif⁸  Karim Dorgham⁸  Guy Gorochov⁸  Audrey Mohr⁸  Christophe Parizot⁸  Melissa Saichi⁸  Paul Quentric⁸  Sonia Burrel⁹  Anne-Geneviève Marcelin⁹  Stéphane Marot⁹  Vincent Calvez⁹  David Boutolleau⁹  François Anna¹⁰  Pierre Charneau¹⁰  Delphine Sterlin¹¹ 

[1] 0Sorbonne Université, Inserm UMRS Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France;

[2] 1Service de la pharmacie, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France;

[3] 2Genalyte Inc., San Diego, CA, United States;

[4] Service de Médecine Intensive Réanimation, Institut de Cardiologie, APHP, Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, France;

[5] Service de Médecine Intensive-Réanimation, APHP, Hôpital Pitié-Salpêtrière, Paris, France;

[6] Service de Médecine Interne 2, Institut E3M, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France;

[7] Sorbonne Université, INSERM, UMRS 1166-ICAN Institute of Cardiometabolism and Nutrition, Paris, France;

[8] Sorbonne Université, Inserm, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France;

[9] Sorbonne Université, Inserm, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Service de Virologie, Paris, France;

[10] Theravectys, Paris, France;

[11] Unit of Antibodies in Therapy and Pathology, Institut Pasteur, Paris, France;

[12] Unité de Virologie Moléculaire et Vaccinologie, Institut Pasteur, Paris, France;

关键词: COVID-19;    humoral immune response;    coronaviral infection;    IgG;    IgA;   

DOI  :  10.3389/fimmu.2022.790334

来源: DOAJ

【 摘 要 】

The capacity of pre-existing immunity to human common coronaviruses (HCoV) to cross-protect against de novo COVID-19is yet unknown. In this work, we studied the sera of 175 COVID-19 patients, 76 healthy donors and 3 intravenous immunoglobulins (IVIG) batches. We found that most COVID-19 patients developed anti-SARS-CoV-2 IgG antibodies before IgM. Moreover, the capacity of their IgGs to react to beta-HCoV, was present in the early sera of most patients before the appearance of anti-SARS-CoV-2 IgG. This implied that a recall-type antibody response was generated. In comparison, the patients that mounted an anti-SARS-COV2 IgM response, prior to IgG responses had lower titres of anti-beta-HCoV IgG antibodies. This indicated that pre-existing immunity to beta-HCoV was conducive to the generation of memory type responses to SARS-COV-2. Finally, we also found that pre-COVID-19-era sera and IVIG cross-reacted with SARS-CoV-2 antigens without neutralising SARS-CoV-2 infectivity in vitro. Put together, these results indicate that whilst pre-existing immunity to HCoV is responsible for recall-type IgG responses to SARS-CoV-2, it does not lead to cross-protection against COVID-19.

【 授权许可】

Unknown